← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Glucagon

FDA approved · Rx

Pancreatic peptide hormone

Also known as: GlucaGen, Gvoke, Baqsimi, Gvoke Hypopen 0.5 Mg Auto-Injector, Gvoke Hypopen 1 Mg Auto-Injector, Gvoke Pfs 1 Mg Pre-Filled Syringe, Gvoke Kit, Gvoke Vialdx, Glucagonum, Glucagone

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 1521 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Glucagon is a 29 amino acid peptide hormone made naturally by alpha cells in the pancreas. It raises blood sugar mainly by signaling the liver to break down stored glycogen and release glucose. It is sold as prescription products under names such as GlucaGen, Gvoke, and Baqsimi.

What the evidence shows

Automatic summaryHuman trials

Glucagon is FDA approved for the treatment of severe hypoglycemia, and some formulations are also approved for use as a diagnostic aid to temporarily slow gut movement during radiologic exams. It is backed by a very large body of human research, including more than 1,500 registered trials reaching Phase 4.

Key facts

Molecular formula
C153H225N43O49S
Molecular weight
3482.7 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

1,521registered studies
Phase 4most advanced phase
59completed (sample)
14recruiting (sample)

Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

Phase 4CompletedNCT02089256

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Phase 4RecruitingNCT07191873

Glycaemic Response, Insulinaemic Response, GLP-1 and GIP Testing of Food Product Lines

CompletedNCT04610203

Study of Tirzepatide for Recovery and Alcohol Use Management

Phase 2RecruitingNCT06727331

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

58,679papers referencing Glucagon

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

N Engl J Med2016

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

N Engl J Med2016

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Lancet2006

Tirzepatide Once Weekly for the Treatment of Obesity.

N Engl J Med2022

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.